Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online during ASN Kidney Week 2020 Reimagined October 19-October 25.
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.
A team of researchers at the Norwegian University of Science and Technology (NTNU) investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.
Professor Mark Cragg speaks to News-Medical about his research which involves turning autoimmunity drugs into anti-cancer treatments.
ANCA-associated vasculitis (AAV) is a systemic disease involving the formation of special autoantibodies (so-called anti-neutrophil cytoplasmic antibodies/ANCA) and vascular inflammation.
Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy.
The ongoing COVID-19 pandemic has caused nearly five million cases and over 327,000 deaths worldwide. The signs and symptoms of this disease are varied, although there are typical features which assist diagnosis.
Patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma now have a new treatment option--a combination of the targeted agent ibrutinib with the immunologic agent rituximab.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912.
Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle.
Tailored T-cells specially designed to combat a half dozen viruses are safe and may be effective in preventing and treating multiple viral infections, according to research led by Children's National Hospital faculty.
Pemphigus, an autoimmune disease mediated by B cells and which causes painful blisters and sores on the skin and mucous membranes, is a rare chronic autoimmune condition that can be fatal if not treated.
Juvenile immune arthritis (JIA) is a severely undertreated condition, and new medications are badly needed to relieve the signs and symptoms of the illness, according to a new study presented at the 2019 ACR/ARP Annual Meeting.
New research discovered that tocilizumab is more effective than rituximab in achieving low disease activity in patients with rheumatoid arthritis whose synovial tissue show a low level of B cell infiltration and did not respond to conventional synthetic disease-modifying anti-rheumatic drugs (conventional synthetic DMARDs) or tumor necrosis factor inhibitors first.
A new study found that very few serious infections were seen in children born to mothers with chronic inflammatory diseases who used non-TNFi biologics or tofacitinib during pregnancy compared to children not exposed to these drugs and children exposed to TNFi biologics in utero.
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis, despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics).
Value in Health, the official journal of ISPOR- the professional society for health economics and outcomes research, announced today the publication of new research from The Netherlands showing important gaps in the deployment of "coverage with evidence development," a type of pharmaceutical managed entry agreement that gives patients access to treatments while additional evidence is being collected.
Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.
A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed marginal zone lymphoma.